Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PositiveID (PSID) Partners with Leading Diabetes Research Organizations to Bring Products to Market

|Includes: PositiveID Corp. (PSID)

PositiveID Corp., a developer of medical technologies for diabetes management and molecular diagnostic systems, today announced its new partnership with the Diabetes Research Institute (NYSE:DRI) at the University of Miami and Schneider Children’s Medical Center of Israel (Schneider Children’s). Through collaborative research, the partnership will support the continued development and study of PositiveID’s diabetes management products.

“We believe that joining forces with the DRI and Schneider Children’s, two of the world’s foremost diabetes research organizations, will enable us to accelerate the remaining development and study of our non-invasive diabetes management projects, and ultimately bring these ground-breaking products to market,” PositiveID chairman and CEO William J. Caragol stated in the press release.

PositiveID is currently developing Easy Check™, a non-invasive breath glucose detection device; GlucoChip™, a continuous glucose-sensing microchip; and the iglucose™ glucometer, a blood glucose meter equipped with PositiveID’s FDA-cleared iglucose technology.

Easy Check is a non-invasive breath glucose detection device that serves as an alternative to pricking a patient’s finger to get blood sugar readings. Easy Check is currently in development in Israel.

GlucoChip is an in vivo continuous glucose-sensing microchip based on PositiveID’s patented “Embedded Bio-Sensor System” coupled with the company’s FDA-cleared RFID implantable microchip. PositiveID says this system will allow people with diabetes to monitor glucose levels in a less invasive manner than current monitoring systems.

PositiveID’s iglucose mobile health system was cleared by the FDA in November 2011. The system allows individuals with diabetes to share, at user consent, blood glucose readings with family members, caregivers and healthcare professionals via text message, e-mail or fax.

“The DRI is intently focused on finding a cure for diabetes, and we believe that working with respected authorities like Professor Phillip and Schneider Children’s can help us reach our goal. While we continue to pursue our primary goal, we also look to develop the most promising research and technology advances, like those being developed by PositiveID, to improve the lives and outcomes of people affected by diabetes. We look forward to working with Schneider Children’s and are pleased to continue our relationship with the PositiveID team,” Jay Skyler, M.D., deputy director of the DRI stated.

For more information visit PositiveIDCorp.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net